Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

被引：20

作者：

Grosicki, Sebastian ^{[1
]}

Mellqvist, Ulf-Henrik ^{[2
]}

Pruchniewski, Lukasz ^{[3
]}

Crafoord, Jacob ^{[4
]}

Trudel, Suzanne ^{[5
]}

Min, Chang-Ki ^{[6
]}

White, Darrell ^{[7
,8
]}

Alegre, Adrian ^{[9
]}

Hansson, Markus ^{[10
]}

Ikeda, Takashi ^{[11
]}

Sunami, Kazutaka ^{[12
]}

Leip, Eric ^{[13
]}

Kudla, Arthur ^{[13
]}

Finn, Gregory ^{[14
]}

Koh, Youngil ^{[15
]}

机构：

[1] Med Univ Silesia, Dept Hematol & Canc Prevent, Katowice, Poland

[2] South Elfsborg Hosp, Dept Hematol, Boras, Sweden

[3] Ctr Med Pratia Poznan, Poznan, Poland

[4] Orebro Univ Hosp, Dept Hematol, Orebro, Sweden

[5] Princess Margaret Canc Ctr, Div Hematol, Toronto, ON, Canada

[6] Catholic Univ Korea, Coll Med, Dept Hematol, Seoul St Marys Hosp, Seoul, South Korea

[7] Dalhousie Univ, Div Hematol, Halifax, NS, Canada

[8] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada

[9] Univ Hosp La Princesa, Dept Hematol, Madrid, Spain

[10] Sahlgrens Univ Hosp, Dept Hematol, Gothenburg, Sweden

[11] Shizuoka Canc Ctr, Div Hematol & Stem Cell Transplantat, Shizuoka, Japan

[12] Natl Hosp Org Okayama Med Ctr, Dept Hematol, Okayama, Japan

[13] Pfizer Inc, Cambridge, MA USA

[14] Pfizer Inc, Early Clin Dev, Cambridge, MA USA

[15] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

来源：

关键词：

D O I：

10.1182/blood-2022-162738

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：4407 / 4408

页数：2